C&EN logo The Newsmagazine of the Chemical World
Home Current Issue ChemJobs Join ACS
Latest News
Government & Policy
Careers and Employment
ACS News
How to log in
Contact Us
Site Map
About C&EN
About the Magazine
How to Subscribe
How to Advertise

Latest News RSS Feed

latest news RSS feedWhat is this?

Join ACS
Join ACS
  Latest News  
  September 6,  2004
Volume 82, Number 36
p. 12


Iminosugars may provide leads for new class of tuberculosis drugs

SIMPLE SUGARS Nitrogen-containing monosaccharides inhibit TB-enzyme activity.
Scientists in England have designed and synthesized the first inhibitors of an enzyme that is essential for the survival of the tuberculosis bacterium [Org. Biomol. Chem., 2, 2418 (2004)]. The compounds might lead to better treatments for TB, which annually infects 8 million to 10 million people and kills 2 million to 3 million.

Mycobacterium tuberculosis can survive in humans for years under the protection of a waxy outer coat of its cell wall. Researchers hope that the new compounds will disrupt production of that coating and kill the bacterium.

"Our paper describes inhibitors of a transferase enzyme for which no previous inhibitors have been reported," says University of Nottingham chemist Neil R. Thomas, who carried out the research with coworkers there and at the University of Birmingham.

The compounds, two iminosugars, inhibit the biosynthesis of polysaccharides known as galactans. The main constituents of the galactans, galactofuranose residues, are not encountered in mammalian metabolism. Therefore, galactan biosynthesis constitutes an attractive target for potential new TB drugs lacking deleterious side effects, the authors observe.

The biosynthesis involves two enzymes. One, uridine diphosphate galactopyranose (UDP-Galp) mutase, catalyzes the conversion of UDP-Galp to its furanose counterpart UDP-Galf. The other, UDP-Galp transferase, catalyzes the transfer of UDP-Galf onto a growing oligosaccharide chain.

"Disrupting the production of the cell wall is known to kill the bacteria, and this is how current drugs work," Thomas explains. "However, the bacteria are rapidly developing resistance to established therapies, and the World Health Organization has a target to get one new drug on the market by 2007 and another by 2012."

Although the two iminosugars exhibit only moderate inhibitory activity against mycobacterial galactan biosynthesis, Thomas and coworkers hope that their compounds will provide a starting point for the development of more potent transferase inhibitors that could be considered for clinical trials.

  Chemical & Engineering News
ISSN 0009-2347
Copyright © 2004

Related Stories
Drug target for tuberculosis
[C&EN, Jul. 26, 2004]  
Drug target for tuberculosis
[C&EN, May 17, 2004]  

E-mail this article
to a friend
Print this article
E-mail the editor